Systemic effects of transdermal testosterone for the treatment of microphallus in children

Pediatr Int. 2001 Apr;43(2):134-6. doi: 10.1046/j.1442-200x.2001.01353.x.

Abstract

Objectives: To elucidate the metabolic effects of topical testosterone for the treatment of microphallus in children.

Methods: We administered 5% testosterone ointment to 50 prepubertal boys for the treatment of microphallus, allowing us to observe its metabolic effect on plasma concentrations of testosterone as a marker of transdermally absorbed testosterone, insulin-like growth factor (IGF)-I as a marker of growth hormone secretion status, and osteocalcin as a marker of bone metabolic turnover.

Results: Transdermal application of testosterone for 30 days at a dose that affects penile growth increased mean (+/-SD) plasma testosterone concentrations from 7.5+/-5.1 to 31.0+/-8.2 ng/dL (pre- vs. post-treatment, respectively; P<0.01). This was associated with a slight but statistically significant elevation of IGF-I concentrations (117.2+/-76.9 vs. 154.4+/-81.5 ng/mL; P<0.05). No significant change in osteocalcin levels was found.

Conclusions: When using testosterone ointment as a treatment for microphallus, it should be borne in mind that this application has systemic effects.

MeSH terms

  • Administration, Cutaneous
  • Biomarkers / blood
  • Bone and Bones / metabolism*
  • Child
  • Child, Preschool
  • Humans
  • Hypogonadism / drug therapy*
  • Hypogonadism / metabolism
  • Infant
  • Insulin-Like Growth Factor I / metabolism*
  • Male
  • Osteocalcin / blood
  • Testosterone / administration & dosage
  • Testosterone / pharmacology*
  • Testosterone / therapeutic use*

Substances

  • Biomarkers
  • Osteocalcin
  • Testosterone
  • Insulin-Like Growth Factor I